Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01393704 · ClinicalTrials.gov registry record · Phase 4
Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial
A Phase 4 study of Blood Loss, Surgical, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 152
- Enrollment target
- 1
- Study location
NCT01393704 is a Phase 4 study of Blood Loss, Surgical that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 152 participants, above the 111-participant average among 6 other Blood Loss, Surgical trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01393704, a Phase 4 study of Blood Loss, Surgical, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 152 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to compare blood loss at the time of laparoscopic or robotically-assisted laparoscopic myomectomy when using different amounts of dilute vasopressin solution. Myomectomy is a surgical procedure to remove fibroids from the uterus. Vasopressin is a synthetic drug used to help decrease blood loss at the time of gynecologic surgery; although very little is know about the optimal dosage and administration. The investigators plan to perform a randomized clinical trial on patients scheduled for minimally invasive myomectomy. All patients will get the same overall amount of vasopressin. Patients will be assigned by chance to one of two groups: one group will receive higher volume of a more dilute vasopressin solution. The other group will receive a lower volume of a more concentrated solution. The investigators will collect information on operative blood loss and complications related to surgery.
Conditions Studied
Interventions
- DRUG Vasopressin
Study Locations (1)
Massachusetts
- Brigham&Women's hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01393704
The ClinicalTrials.gov registry entry for NCT01393704 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 111-participant average among 6 other Blood Loss, Surgical trials with a reported enrollment target (37% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Blood Loss, Surgical appearing as the primary indexed condition, and to 1 intervention - of which Vasopressin is the first listed.
NCT01393704 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01393704 about?
NCT01393704 is a clinical study titled "Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial". The main purpose of this study is to compare blood loss at the time of laparoscopic or robotically-assisted laparoscopic myomectomy when using different amounts of dilute vasopressin solution. Myomectomy is a surgical procedure to remove fibroids from the uterus. Vasopressin is a synthetic drug used...
What is the current status of trial NCT01393704?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 152 participants. The study started on 2011-07. Estimated completion is 2015-06.
What conditions does trial NCT01393704 study?
This clinical trial studies the following conditions: Blood Loss, Surgical.
What interventions are being tested in trial NCT01393704?
The interventions under investigation include: Vasopressin (DRUG).
Who is sponsoring clinical trial NCT01393704?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01393704 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Loss, Surgical
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
RECRUITING · Phase 4
-
PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding
COMPLETED · Phase 4
-
Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery
COMPLETED · Phase 4
-
Tranexamic Acid in Adult Spinal Deformity Surgery
RECRUITING · Phase 3
-
Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony
RECRUITING · Phase 2
-
Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.